Showing 1541-1550 of 2527 results for "".
- New Peptide Serum Complements In-Office Aesthetic Treatmentshttps://modernaesthetics.com/news/new-peptide-serum-complements-in-office-aesthetic-treatments/2485257/ZO® Skin Health has introduced the Peptide Facial Refining Concentrate, an advanced at-home serum formulated to complement professional aesthetic procedures and enhance overall facial rejuvenation. The launch adds to the company’s physician-dispensed portfolio with
- Modern Aesthetics: Enhanced Content in a New Digital Formathttps://modernaesthetics.com/news/modern-aesthetics-enhanced-content-in-a-new-digital-format/2484800/Modern Aesthetics’ mission is to deliver actionable, expert-driven content covering injectables, surgery, energy-based devices, skin care, regenerative medicine, and practice development. Fulfilling that mission involves changing along with evolving reader preferences and broader industr
- RVL Pharmaceuticals Announces New CEO, Chief Growth Officerhttps://modernaesthetics.com/news/rvl-pharmaceuticals-announces-new-ceo-chief-growth-officer/2484615/RVL Pharmaceuticals, Inc. has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer, signaling a strategic leadership shift aimed at accelerating growth for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Deo, who previously se
- Natural Refinement, Early Intervention Define 2026 Aesthetic Trends, Says Dr Anil Shahhttps://modernaesthetics.com/news/natural-refinement-early-intervention-define-2026-aesthetic-trends-says-dr-anil-shah/2483940/Facial plastic surgeon Anil Shah, MD, outlined six key trends shaping aesthetic surgery in 2026 in a recent press release, reflecting a shift toward holistic, age-conscious, and safety-driven approaches. A full-face rejuvenation approach is supplanting isolated interventions, according to
- SkinMedica Updates Packaging, Launches New HA5 Moisturizerhttps://modernaesthetics.com/news/skinmedica-updates-packaging-launches-new-ha5-moisturizer/2483916/Allergan Aesthetics, a division of AbbVie, announced a comprehensive redesign of its SkinMedica® product packaging aimed at improving user experience and reducing environmental impact. The updated packaging includes a modernized logo, copper accents, and simplified
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://modernaesthetics.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s
- New HA Filler Obagi® saypha® MagIQ™ Approved by FDAhttps://modernaesthetics.com/news/new-ha-filler-obagi-saypha-magiq-approved-by-fda/2483329/The US Food and Drug Administration (FDA) has approved Obagi® saypha® MagIQ™, an injectable hyaluronic acid (HA) gel, marking the first product in the Obagi® saypha® collection under the Obagi Medical brand, Waldencast plc announced.
- Allergan Aesthetics Expands SkinMedica® Line with New Hydrating Cleanserhttps://modernaesthetics.com/news/allergan-aesthetics-expands-skinmedica-line-new-hydrating-cleanser/2483005/Allergan Aesthetics, an AbbVie company, has introduced the latest addition to its SkinMedica® HA5® Hydra Collagen portfolio: the HA5® Hydra Collagen Hydrating Foaming Cleanser. The cleanser combines the brand’s proprietary HA5® Hydra Collagen Complex—five forms of hyaluronic acid blended w
- New Website Streamlines Laser Therapy Device Selectionhttps://modernaesthetics.com/news/new-website-streamlines-laser-therapy-device-selection/2482984/ColdLasers.org has launched LaserTherapy.com, a redesigned platform aimed at simplifying the process of selecting therapeutic laser devices. The site offers a modern interface, comparison tools, and updated educational content designed to support informed decision-making. The platform addr
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie